readthroughSign in
Nov 13, 2026People

Moderna's chief legal officer Shannon Klinger to retire under agreement filed November 13

Klinger will remain through March 2027 under a retirement deal that includes payments tied to the outcome of ongoing litigation.

Moderna, Inc. disclosed in an 8-K filed November 13, 2026 that it had entered into a Transitional Services and Retirement Agreement with Shannon Thyme Klinger, the company's Chief Legal Officer, setting out the terms of her retirement.1

Under the agreement, Klinger will continue employment with the company until March 31, 2027, transitioning her duties as requested, and will be deemed to have resigned from all officer positions on the earlier of that date or a date designated by the company.1 Until then, she will keep receiving her current base salary and benefits and continue vesting in outstanding equity awards.1 She is also eligible for a 2026 performance bonus based on her target bonus multiplied by the corporate performance factor set by the board.1

After the retirement date, Klinger will receive severance paid in equal biweekly installments over twelve months, totaling $1,628,300, representing twelve months of base salary plus her current annual target bonus.1 Moderna will also cover her COBRA premiums until September 30, 2028, subject to earlier termination if she gains other health coverage or loses COBRA eligibility.1

The agreement additionally ties further payments to pending litigation outcomes. Klinger could receive $2,500,000 if Moderna prevails in all current and related future litigation with Arbutus Biopharma Corporation and Genevant Sciences, GmbH, and up to $5,500,000 depending on the outcome of current and related future litigation with Pfizer, Inc., BioNTech SE and related parties.1 The filing does not specify the subject matter of these proceedings beyond calling them litigation.

The agreement includes releases of claims and other standard terms.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.